Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab in Acquired Hemophilia A
NCT05345197Phase 2Active, not recruiting
- Sponsor
- University of Washington
- Start
- Aug 2022
- Primary completion
- Jul 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of emicizumab in acquired hemophilia A (AHA), sponsored by University of Washington. Started Aug 2022; status: active, not recruiting.
02
Drugs
emicizumab
03
Conditions
acquired hemophilia A (AHA)
Beyond the preview
Go deeper on NCT05345197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05345197.